SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif. , July 14, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding... Read More

Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 8, 2025 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today... Read More

SOUTH SAN FRANCISCO , USA and VANCOUVER, Canada , March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (" ESSA " or the " Company ") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General... Read More

Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 11, 2025 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate... Read More

Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 17, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing... Read More

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination of... Read More

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. After 15.2 months... Read More

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept. 11, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024 , at 9:10 a.m. ET in New York, NY . David R.... Read More

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting... Read More

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT . David R. Parkinson , President and Chief Executive... Read More

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York . David. R. Parkinson,... Read More

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in... Read More

SOUTH SAN FRANCISCO , Calif. and VANCOUVER, BC , April 9, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 2:30 p.m. ET in Toronto, Canada.... Read More

SOUTH SAN FRANCISCO , USA and VANCOUVER, CANADA , March 7, 2024 /CNW/ - ESSA Pharma Inc . (" ESSA " or the " Company ") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the " Meeting "). At the... Read More

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 masofaniten plus enzalutamide combination dose expansion study ongoing Cash runway sufficient to fund operations... Read More

SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , Feb. 6, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Tuesday, February 13,... Read More

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. While... Read More

Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expansion underway evaluating masofaniten (EPI-7386)/enzalutamide combination versus enzalutamide monotherapy in patients with mCRPC SOUTH SAN FRANCISCO, California and... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35 th Annual Healthcare Conference on Thursday, November 30 , 2023, at 12:00 p.m. ET in New York.... Read More

SOUTH SAN FRANCISCO , Calif. and VANCOUVER, Canada , Nov. 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London. David. R.... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 6, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023 . Under the ATM Sales... Read More

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently enrolled into cohort four, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 56% of patients achieved PSA <0.2mg/mL SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 26, 2023 /CNW/ -... Read More

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently enrolled into cohort four, 69% of patients achieved PSA90, 63% of patients achieved PSA90 in less than 90 days, and 56% of patients achieved PSA <0.2mg/mL SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Oct. 21, 2023 /CNW/ - ESSA... Read More

Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 results selected for a poster presentation at ESMO 2023 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Sept. 18, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company... Read More

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Aug. 31, 2023 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that each of its President and Chief Executive Officer, David R Parkinson and its Executive Vice President and Chief Operating Officer, Peter Virsik (collectively,... Read More

Completion of the Phase 1 EPI-7386 combination study with Xtandi ® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into clinical trial support agreement with Janssen to supply Erleada ® (apalutamide) and Zytiga ® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin... Read More

SOUTH SAN FRANCISCO , California and VANCOUVER, Canada , June 6, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino , M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 1, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York . David R. Parkinson... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , May 11, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York . David R.... Read More

Entered into clinical trial support agreement with Janssen to supply Erleada ® (apalutamide) and Zytiga ® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Continue to enroll patients into the fourth cohort of the Phase 1 EPI-7386 combination study with Xtandi ® (enzalutamide); Phase 1 completion expected in 3Q2023 followed by initiation of the... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , April 18, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 2:00 p.m. Eastern Time.... Read More

SOUTH SAN FRANCISCO, Calif. , and VANCOUVER, Canada , April 12, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial support agreement (the "Agreement") with Janssen Research & Development, LLC ("Janssen") to enable... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , March 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33 rd Annual Healthcare Conference on Wednesday, March 15, 2023 , at 11:20 a.m. Eastern Time.... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 13, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that further analyses of initial clinical data from two Phase 1 studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer ("mCRPC")... Read More

Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, Canada , Feb. 7, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies... Read More

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 2, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will participate in a fireside chat at the Guggenheim Healthcare Talks 5th Annual Oncology Conference in New York City on Thursday, February... Read More

SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA , Dec. 13, 2022 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022 . All references to "$" in this release refer to United States... Read More